Cantor Fitzgerald hosted its Virtual Muscular Dystrophy Symposium from April 2-3, 2024.

The symposium featured two days of discussions and fireside chats with muscular dystrophy companies, innovators, physicians, and specialists. The discussions were moderated by Cantor's Biotechnology Equity Research team, and delved into topics including: 

• How will available therapies (including gene therapy in DMD) influence patient uptake and access to pipeline candidates.
• The latest on regulatory and commercial trends in Duchenne Muscular Dystrophy (DMD) gene therapy.
• Which clinical endpoints give experts the most confidence.
• How to interpret trial results in heterogeneous muscular dystrophy indications.
• What is next for RNA- and oligo-based therapies and why patients and providers could choose one over the other.
• When to target the genetic defect in muscular dystrophy (such as dystrophin in DMD) vs. targeting inflammation/fibrosis.